Ocera Therapeutics
OCRX
OCRX was delisted on the 8th of December, 2017.
33 hedge funds and large institutions have $14.7M invested in Ocera Therapeutics in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
6% less capital inflows, than outflows
Capital inflows: $1.69M | Capital outflows: $1.8M
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
+$1.31M |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
+$197K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$65.7K |
| 4 |
Renaissance Technologies
New York
|
+$59.7K |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Turner Investments
Berwyn,
Pennsylvania
|
-$816K |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$549K |
| 3 |
Weiss Multi-Strategy Advisers
New York
|
-$221K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$89.3K |
| 5 |
Virtu KCG Holdings
New York
|
-$39K |
OCRX Hedge Fund Activity: Q2 2016 in Review
33 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics (OCRX) for Q2 2016, worth a combined $14.7M — down 36% from $22.9M a quarter earlier.
Fund positioning in OCRX was balanced in Q2 2016: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 10 trimmed.
The largest buyer was Deerfield Management, adding an estimated $1.31M. The largest seller was Turner Investments, cutting an estimated $816K.
- 33 institutional investors held Ocera Therapeutics (OCRX) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $14.7M of Ocera Therapeutics stock for Q2 2016, down 36% quarter-over-quarter.
- 3 funds opened new Ocera Therapeutics positions in Q2 2016 and 3 closed out, a net change of 0 holders.
- The largest Ocera Therapeutics buyer in Q2 2016 was Deerfield Management, an estimated $1.31M added.
- The largest Ocera Therapeutics seller in Q2 2016 was Turner Investments, an estimated $816K sold.
Based on aggregated 13F filings for Q2 2016.